Gene Editing for Lipids: 1-Year CTX310 Data, With Luke Laffin, MD
A single infusion of CTX310, an investigational in vivo CRISPR-Cas9 gene-editing therapy targeting ANGPTL3, produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides through 1 year of follow-up in a phase 1a trial, according to data …